Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Farudodstat may effectively treat alopecia areata without harmful side effects.

Farudodstat may effectively treat alopecia areata without harming hair follicles.

Farudodstat may help treat alopecia areata by protecting hair follicles.

This study found that activating hair follicle resident T cells in a human organ culture can induce an alopecia areata-like immune response, and that the drug farudodstat partially reduced this effect.

In this study, the researchers used a human hair follicle model to demonstrate that T cell stimulation can induce an alopecia areata–like phenotype, with cell proliferation and immune privilege collapse; however, the DHODH inhibitor farudodstat partially mitigated these effects by reducing T cell proliferation.

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

This review explores the shared pathogenesis of alopecia areata and vitiligo and compares treatment responses, noting that hair regrowth in alopecia areata occurs more rapidly than skin re-pigmentation in vitiligo, possibly due to differences in stem cell biology and treatment effects on melanocytes.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This study introduces an extended approach to the Bonferroni procedure that accounts for correlations among endpoints, aiming to improve test power while maintaining strong control of the family-wise type I error rate in clinical trials.

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

The researchers reported that during early embryogenesis and larval development in Silurana tropicalis, inhibiting steroidogenic enzymes cyp19 and srd5beta affects genes related to thyroid and reproductive systems.

This study examined the effectiveness of FT-Raman spectroscopy for detecting polymorphism in Lamivudine and Finasteride, highlighting its advantages over other methods due to its capability to provide sharp, well-resolved spectral bands and reduced sampling issues.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.

This study found that using electronic healthcare record data can provide valuable early insights into the clinical context of about half of the new safety signals evaluated within a regulatory environment.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This study found no correlation between clinical signs and sex steroid levels in ferrets with hyperadrenocorticism and noted that androstenedione was elevated in many cases.

This research overview discusses Post-Finasteride Syndrome, presenting data from an FDA database, but it does not report any new clinical findings.

In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.

This study validated an HPLC analytical method for evaluating fenasteride in commercial products, finding it to be sensitive, selective, and within acceptance criteria for specificity, precision, and stability, making it suitable for quality control testing.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.